Altarac S
Department of Biology, School of Medicine, University of Zagreb.
Acta Med Croatica. 1993;47(1):19-22.
By using polyacrylamide gel electrophoresis, sera were tested on cancer-associated globulin from female patients bearing gynaecological cancers: 45 cervical, 21 endometrial and 38 ovarian. As a control, normal sera were taken from 97 healthy women. Sera were also taken from patients with benign neoplasias: 59 cervical dysplasias, 72 endometrial fibromyomas and 47 ovarian cystadenomas. The cancer-associated globulin was evaluated, as an antibody to a cancer antigen that consists of ceramide-lactoside conjugated to a protein integrated in a tumor cell membrane. This serum globulin can be shown densitometrically as the fourth post-transferrin peak (PTP 4). It was found in 69% cervical cancer patients, 52% of the endometrial cancer patients and 89% of the ovarian cancer patients. False positive results were detected in 11% of the normal sera and 25% of the sera from patients with benign neoplasias.
通过聚丙烯酰胺凝胶电泳，对患有妇科癌症的女性患者的血清进行了癌症相关球蛋白检测：45例宫颈癌患者、21例子宫内膜癌患者和38例卵巢癌患者。作为对照，从97名健康女性中采集了正常血清。还从患有良性肿瘤的患者中采集了血清：59例宫颈发育异常、72例子宫内膜纤维瘤和47例卵巢囊腺瘤。对癌症相关球蛋白进行了评估，它是一种针对癌症抗原的抗体，该抗原由与整合在肿瘤细胞膜中的蛋白质结合的神经酰胺乳糖苷组成。这种血清球蛋白可以通过密度测定法显示为转铁蛋白后第四个峰（PTP 4）。在69%的宫颈癌患者、52%的子宫内膜癌患者和89%的卵巢癌患者中发现了这种球蛋白。在11%的正常血清和25%的良性肿瘤患者血清中检测到假阳性结果。
